Skip to main content
S&P 5007,722.72+0.73%DOW51,176.96+0.49%NASDAQ27,190.86+1.19%BTC$84,654.00-0.13%ETH$2,677.39-1.09%GOLD$4,172.10-0.72%OIL$91.26-1.73%
Smart Investors Daily
SID Premium
BridgeBio Pharma, Inc. logo

NASDAQ · BBIO

BridgeBio Pharma, Inc.

Healthcare · Biotechnology

$67.25

Up+$0.34 (+0.51%)

Updated Oct 4, 2026, 8:30 AM

SID Score

5.1/10

Composite research score

Smart Money

58/100

Neutral

Market cap
14.11B
P/E ratio
-17.71
Dividend yield
0.00%
52-week range
$52.00 – $93.42
Volume
2.65M
Avg. volume
2.32M

Price performance · BBIO

BBIO price history

1M range · 0 trading sessions · Daily adjusted prices

BBIO does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest BBIO news

The latest Smart Investors Daily articles mentioning BBIO.

Stock researchCompany · Overview

BBIO research

Overview

Company profile and research snapshot.

Company profile

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$85.00
Implied upside
—
Analysts
—
BBIO recent ratings
DateFirmRatingTarget
Sep 10, 2026HC Wainwright & Co.Buy—
Sep 2, 2026HC Wainwright & Co.Buy—
Sep 1, 2026MizuhoOutperform—
Aug 12, 2026Canaccord GenuityBuy—
Aug 12, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Jefferies Highlights Three Biotech Stocks With Blockbuster Potential

Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.

Yahoo · Sep 27, 2026

The Bull Case For BridgeBio Pharma (BBIO) Could Change Following New ATTR Data Versus Tafamidis

Earlier this week, BridgeBio Pharma reported peer-reviewed real-world data in Cardiology and Therapy showing that its ATTR cardiomyopathy therapy acoramidis was associated with lower early clinical worsening risk versus tafamidis in newly treated patients over a mean follow-up of 4.6 months. The study offers the first head-to-head, real-world comparison between approved transthyretin stabilizers, potentially strengthening the clinical and commercial positioning of acoramidis as Attruby in...

Yahoo · Sep 27, 2026

BridgeBio Pharma (BBIO) Stock Looks Reasonable As Fresh Acoramidis Data Lands

BridgeBio Pharma has delivered a strong share price run in recent years, and that kind of move naturally raises the question of whether the current valuation still lines up with the sales that sit behind the story. With fresh real world data around its acoramidis therapy now in the mix, investors are asking how much revenue power is realistically being priced into the stock today. Over the past 3 years the stock has gained 148.7%, which puts real pressure on the question of how much sales...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By